Neptune and Acasti Welcome Professor Ruth McPherson to Acasti's Scientific Advisory Board
April 22 2010 - 7:30AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) and Acasti Pharma Inc.
("Acasti") are pleased to announce the expansion of Acasti's
Scientific Advisory Board ("SAB") by welcoming Pr Ruth McPherson,
MD, PhD to join Pr Steven Nissen (Cleveland Clinic), Pr. William
Harris (Sandford Research/USD), Pr Thomas G. Hartman (Rutgers
University Center) and Dr. Magdy M. Abdel-Malik (Quaestio
Global Partners).
Dr. McPherson is a Professor (Departments of Medicine &
Biochemistry, University of Ottawa), Director of Research (Division
of Cardiology) and Director of the Lipid Clinic &
Atherogenomics Laboratory at the University of Ottawa Heart
Institute. She co-authored the current Canadian Cardiovascular
Society / Canadian guidelines for the diagnosis and treatment of
dyslipidemia and prevention of cardiovascular disease, and a member
of several Editorial Boards and Clinical Guideline
Committees. Pr. McPherson is a member of the Atherosclerosis,
Genetics & Cell Biology group at the University of
Ottawa. Her work on the genetics of coronary artery disease
led to the identification of a risk locus on chromosome 9p21
published in Science in 2007. Through her research on HDL
receptors she has identified a novel pathway for selective uptake
of HDL-CE that involves uptake, delipidation and recycling of HDL
back to apical surface. These studies are relevant to understanding
reverse cholesterol transport and may result in novel therapies to
increase the functionality of HDL and prevent or treat
cardiovascular disease. She has co-authored over 120 peer-reviewed
publications and obtained solid research funding for over 20 years.
She currently holds the Merck Frosst Canada Chair in
Atherosclerosis Research.
"Acasti is and will continue to be committed to excellence; we
demonstrate this by welcoming Pr McPherson to join the other four
renowned members of our SAB. We are fortunate to be allowed to
benefit from her valuable advice, critic and her considerable
expertise in the field of dyslipidemia and reverse cholesterol
transport," said Dr. Bruno Battistini, Senior Director
Pharmaceutical R&D of Acasti.
"Pr McPherson is a key Canadian opinion leader in the area of
clinical lipidology and cardiovascular risk reduction with an
outstanding implication in the Canadian and international medical
scientific communities," said Tina Sampalis, President of Acasti
Pharma Inc. "We have built our SAB stronger than ever ready to move
forward since Acasti has recently received positive and encouraging
guidance from Health Canada during a pre- clinical trial
application (pre-CTA) consultation meeting," she added.
"I am delighted that Dr. Sampalis contacted me and introduced
Acasti as an emerging biopharma. Acasti's product portfolio is
innovative and fits perfectly with my area of research. I am
looking forward to contribute in the development of a new and
natural approach to manage lipid dysfunction potentially fulfilling
a treatment gap," said Pr Ruth McPherson.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither NASDAQ nor the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known
and unknown risks, uncertainties, and other unknown factors that
could cause the actual results of the Company to be
materially different from historical results or from any future
results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief,"
"expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally
to other risks and uncertainties that are described from time to
time in the Company's reports filed with the
Securities and Exchange Commission and the Canadian
securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Dr. Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
![](http://www.globenewswire.com/newsroom/ti?nf=MTYwIzE4OTQ1MSMxMTg0OA==)
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024